Elrexfio (elranatamab)

pCPA File Number: 22724
Negotiation Status:
Active Negotiation
Indication(s):
Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy
Sponsor/Manufacturer:
Pfizer Canada ULC
CDA-AMC Project Number:
PC0315-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable